JP2024529452A5 - - Google Patents
Info
- Publication number
- JP2024529452A5 JP2024529452A5 JP2024504971A JP2024504971A JP2024529452A5 JP 2024529452 A5 JP2024529452 A5 JP 2024529452A5 JP 2024504971 A JP2024504971 A JP 2024504971A JP 2024504971 A JP2024504971 A JP 2024504971A JP 2024529452 A5 JP2024529452 A5 JP 2024529452A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- pharmaceutical composition
- hours
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21188741 | 2021-07-30 | ||
| EP21188741.9 | 2021-07-30 | ||
| PCT/EP2022/071281 WO2023006923A1 (en) | 2021-07-30 | 2022-07-28 | Dose regimen for long-acting glp1/glucagon receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529452A JP2024529452A (ja) | 2024-08-06 |
| JP2024529452A5 true JP2024529452A5 (cg-RX-API-DMAC7.html) | 2025-07-30 |
Family
ID=77155646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504971A Pending JP2024529452A (ja) | 2021-07-30 | 2022-07-28 | 長時間作用型ｇｌｐ１／グルカゴン受容体アゴニストのための投薬レジメン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250262279A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4376871A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024529452A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240043778A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117677395A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022320922A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226846A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024000222A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024001276A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023006923A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| TWI617574B (zh) | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
| PL3057984T3 (pl) | 2013-10-17 | 2018-12-31 | Zealand Pharma A/S | Acylowane analogi glukagonu |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| DK3283507T3 (da) * | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
| ES2983409T3 (es) | 2016-03-10 | 2024-10-23 | Medimmune Ltd | Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
| US11352405B2 (en) * | 2017-08-09 | 2022-06-07 | Sanofi | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis |
| US11566057B2 (en) * | 2017-09-25 | 2023-01-31 | Merck Sharp & Dohme Llc | Long-acting co-agonists of the glucagon and GLP-1 receptors |
-
2022
- 2022-07-28 KR KR1020247006953A patent/KR20240043778A/ko active Pending
- 2022-07-28 MX MX2024001276A patent/MX2024001276A/es unknown
- 2022-07-28 CA CA3226846A patent/CA3226846A1/en active Pending
- 2022-07-28 CN CN202280051207.4A patent/CN117677395A/zh active Pending
- 2022-07-28 EP EP22757584.2A patent/EP4376871A1/en active Pending
- 2022-07-28 JP JP2024504971A patent/JP2024529452A/ja active Pending
- 2022-07-28 US US18/291,966 patent/US20250262279A1/en active Pending
- 2022-07-28 WO PCT/EP2022/071281 patent/WO2023006923A1/en not_active Ceased
- 2022-07-28 AU AU2022320922A patent/AU2022320922A1/en active Pending
-
2024
- 2024-01-25 CL CL2024000222A patent/CL2024000222A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024529452A5 (cg-RX-API-DMAC7.html) | ||
| JP2019196370A5 (cg-RX-API-DMAC7.html) | ||
| AU2025220813A1 (en) | Treatment of post-bariatric hypoglycemia with GLP-1 antagonists | |
| ES2620610T3 (es) | Composiciones farmacéuticas de albiglutide | |
| JP2024503265A5 (cg-RX-API-DMAC7.html) | ||
| CN102718858A (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| US20200397690A1 (en) | THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1c | |
| CN102292346A (zh) | 肥胖的治疗 | |
| JP2023501375A5 (cg-RX-API-DMAC7.html) | ||
| Maideen | Pharmacologically relevant drug interactions of glucagon-like peptide-1 receptor agonists | |
| JP2025508786A5 (cg-RX-API-DMAC7.html) | ||
| JP7221956B2 (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP2004525143A5 (cg-RX-API-DMAC7.html) | ||
| JP2022035920A5 (cg-RX-API-DMAC7.html) | ||
| IL323508A (en) | Methods and uses for treating nausea and vomiting | |
| CN102711797A (zh) | 治疗主动脉纤维化的组合物及方法 | |
| Davies et al. | Efpeglenatide: a once monthly GLP-1 RA in the pipeline | |
| King | Advances in insulin therapy: a review of insulin degludec. | |
| JP2005529152A5 (cg-RX-API-DMAC7.html) | ||
| JP2023512487A5 (cg-RX-API-DMAC7.html) | ||
| EP4090351B1 (en) | Dosing regimen of glp-1 | |
| JP2021524858A5 (cg-RX-API-DMAC7.html) | ||
| GB2321190A (en) | Medicament pack for treating Parkinson's Disease | |
| Riedl et al. | Treatment Of Hereditary Angioedema: Safety, Efficacy, And Patient Preference After Switching To Donidalorsen (OASISplus Study) | |
| Kapoor | Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs) |